Cyclerion enters exclusive talks to sell zagociguat/CY3018; CEO to invest $5M

Cyclerion Therapeutics, Inc.

Non-binding proposal from entity including CEO Peter Hecht to buy zagociguat and CY3018 assets.
Independent Board concluded proposal merits pursuit; exclusive negotiation period underway.
Binding agreement for CEO to invest $5M in cash for stock or convertible preferred stock.
CEO equity investment closes 6 business days after definitive asset sale documents signed.
Proceeds intended to support ongoing operations; deal subject to board and shareholder approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.